Nascent Biotech, Inc. Share Price Other OTC
Equities
NBIO
US63108Q1013
Biotechnology & Medical Research
Sales 2022 | 1 79.68 | Sales 2023 | - | Capitalization | 7.16M 571M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -2M -159M | EV / Sales 2022 | 6,213,671 x |
Net cash position 2022 | 94.41K 7.52M | Net Debt 2023 | 217K 17.32M | EV / Sales 2023 | - |
P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-2.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14/07/14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14/07/14 |
Douglas Karas
BRD | Director/Board Member | 59 | 03/04/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14/07/14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14/07/14 |
Douglas Karas
BRD | Director/Board Member | 59 | 03/04/16 |
1st Jan change | Capi. | |
---|---|---|
-1.25% | 103B | |
+8.28% | 101B | |
+4.40% | 23.07B | |
-12.28% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.48% | 16.94B | |
+6.83% | 14.07B | |
+38.28% | 12.35B |